A Review of the Main Considerations for Formulation Development in Preclinical Toxicology Studies

1. Sooben, K . Formulation considerations. In: Healing, G, Green, O, eds. Non-Clinical Vascular Infusion Technology. CRC Press; 2014;Vol. 1:73-112.
Google Scholar2. International Council on Harmonisation (ICH) . M3 (R2), Guidance on Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals. ICH, June 2009.
Google Scholar3. Diehl, K-H, Hull, R, Morton, D, et al. A good practice guide to the administration of substances and removal of blood, including routes and volumes. J Appl Toxicol. 2001;21:15-23.
Google Scholar | Crossref | Medline | ISI4. The Organisation for Economic Co-operation and Development (OECD) . Principles of Good Laboratory Practice, ENV/MC/CHEM (98) 17 (revised in 1997, issued January 1998).
Google Scholar5. The United Kingdom Good Laboratory Practice Monitoring Authority . Medicines and Healthcare Products Regulatory Agency (MHRA): Good Laboratory Practice Regulations 1999, Statutory Instrument 1999 No. 3106; as Amended by the Good Laboratory Practice (Codification Amendments Etc.) Regulations 2004, Statutory Instrument 2004 No. 994.
Google Scholar6. Gad, S. C., Spainhour, C. B., Shoemake, C. et al. Tolerable levels of nonclinical vehicles and formulations used in studies by multiple routes in multiple species with notes on methods to improve utility. Int J Toxicol. 2016;35(2):95-178.
Google Scholar | SAGE Journals | ISI7. International Council on Harmonisation (ICH) . Q3A (R2), Impurities in New Drug Substances. 2006.
Google Scholar8. International Council on Harmonisation (ICH) . Q3B (R2) Note for Guidance on Impurities in New Drug Products. 1999.
Google Scholar9. International Council on Harmonisation (ICH) . Q3C (R6) on impurities: guideline for residual solvents. 2017.
Google Scholar10. Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER) . Guidance, Nonclinical studies for pharmaceutical excipients. 2005.
Google Scholar11. Stranz, M . Advancing the Science of Infusion Therapy – Understanding pH and osmolarityInfusion Nurses Society, Annual Meeting; 2008. https://studylib.net/doc/8127279/understanding-ph-and-osmolarity.
Google Scholar12. Healing, G, Green, O, eds. Non-Clinical vascular infusion technology. CRC Press; 2014. Volumes 1 and 2.
Google Scholar13. Trissel, L . Handbook of Injectable Drugs. 11th ed. Bethesda, MD: American. Society of Health-System Pharmacists; 2001.
Google Scholar14. Weber, K, Mowat, V, Hartmann, E, et al. Pathology in continuous infusion studies in rodents and non-rodents and ITO (Infusion Technology Organisation)-recommended protocol for tissue sampling and terminology for procedure-related lesions. J Toxicol Pathol. 2011;24:113-124.
Google Scholar | Crossref | Medline15. Baker, J . Prestudy analytical assessments: Equipment compatibility. In: Healing, G, Green, O, eds. Non-Clinical vascular infusion technology. Volume 1. CRC Press; 2014:119-126.
Google Scholar16. Tepper, JS, Kuehl, PJ, Cracknell, S, Nikula, KJ, Pei, L, Blanchard, JD. Symposium summary: "Breathe in, breathe out, its easy: What you need to know about developing inhaled drugs". Int J Toxicol. 2016;35(4):376-392.
Google Scholar | SAGE Journals | ISI17. Bujold, K, Pfeiffer, J, Fink, J, Malcolmson, R, Authier, S, Tepper, J. Novel methods for the assessment of safety pharmacology and toxicology parameters in anesthetized and ventilated dogs receiving inhaled drugs. J Pharmacol Toxicol Methods. 2019;99:106578.
Google Scholar | Crossref | Medline18. Dahl, A . Dose concepts for inhaled vapors and gases. Toxicol Appl Pharmacol. 1990;103(2):185-197.
Google Scholar | Crossref | Medline19. Newman, SP . Dry powder inhalers. In: Laurent, G, Shapiro, S, eds. Encyclopaedia of Respiratory Medicine. Elsevier Ltd; 2006:58-64.
Google Scholar | Crossref20. Alexander, DJ, Collins, CJ, Coombs, DW, et al. Association of Inhalation Toxicologists (AIT) working party recommendation for standard delivered dose calculation and expression in non-clinical aerosol inhalation toxicology studies with pharmaceuticals. Inhal Toxicol. 2008;20:1179-1189.
Google Scholar | Crossref | Medline | ISI21. Ganderup, NC, Harvey, W, Mortensen, JT, Harrouk, W. The minipig as nonrodent species in toxicology-where are we now? Int J Toxicol. 2012;31(6):507-528.
Google Scholar | SAGE Journals | ISI22. Shah, SM, Jain, AS, Kaushik, R, Nagarsenker, MS, Nerurkar, MJ. Preclinical formulations: Insight, strategies, and practical considerations. AAPS PharmSciTech. 2014;15(5):1307-1323.
Google Scholar | Crossref | Medline23. Qvist, MH, Hoeck, U, Kreilgaard, B, Madsen, F, Frokjaer, S. Evaluation of Göttingen minipig skin for transdermal in vitro permeation studies. Eur J Pharm Sci. 2000;11(1):59-68.
Google Scholar | Crossref | Medline | ISI24. Wojcinski, Z, Andrews-Jones, L, Aido, D, Dunstan, R. Skin. In: Sahota, PS, Popp, JA, Hardisty, JF, Gopinath, C, eds. Toxicologic Pathology: Nonclinical Safety Assessment. Boca Raton, FL: CRC Press; 2013:831-895.
Google Scholar | Crossref25. Stricker-Krongrad, A, Shoemake, CR, Liu, J, Brocksmith, D, Bouchard, G. The importance of minipigs in dermal safety assessment: An overview. Cutan Ocul Toxicol. 2017;36(2):105-113.
Google Scholar | Crossref | Medline26. Emami, A, Tepper, J, Short, B, et al. Toxicology evaluation of drugs administered via uncommon routes: Intranasal, intraocular, intrathecal/intraspinal, and intra-articular. Int J Toxicol. 2018;37(1):4-27.
Google Scholar | SAGE Journals | ISI27. Laboratory Animal Science Association (LASA) . Good Practice Guidelines – Administration of Substances (Rat, Mouse, guinea Pig and Rabbit); Oct 1998. Series 1/Issue 1.
Google Scholar28. International Council on Harmonisation (ICH) . Guideline S6 (R1), Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals. 2011.
Google Scholar29. Baldrick, P . Safety evaluation of biological drugs: What are toxicology studies in primates telling us? Regul Toxicol Pharmacol. 2011;59:227-236.
Google Scholar | Crossref | Medline | ISI30. Food and Drug Administration (FDA)/Center for Drug Evaluation and Research (CDER) Guidance . Nonclinical Safety Evaluation of Reformulated Drug Products and Products Intended for Administration by an Alternate Route. Guidance for Industry and Review Staff Good Review Practice. 2015 Pharmacology/Toxicology.
Google Scholar

留言 (0)

沒有登入
gif